LLerena A - Search Results

1

Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders.

Rodeiro I, Remírez-Figueredo D, García-Mesa M, Dorado P, LLerena A; CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF. Rodeiro I, et al. Among authors: llerena a. Drug Metabol Drug Interact. 2012;27(1):57-60. doi: 10.1515/dmdi-2012-0006. Drug Metabol Drug Interact. 2012. PMID: 22718626

2

QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy.

LLerena A, Berecz R, de la Rubia A, Dorado P. LLerena A, et al. Eur J Clin Pharmacol. 2002 Jun;58(3):223-24. doi: 10.1007/s00228-002-0452-7. Eur J Clin Pharmacol. 2002. PMID: 12162273 Clinical Trial. No abstract available.

3

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.

Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A. Berecz R, et al. Among authors: llerena a. Eur J Clin Pharmacol. 2003 May;59(1):45-50. doi: 10.1007/s00228-003-0576-4. Epub 2003 Mar 28. Eur J Clin Pharmacol. 2003. PMID: 12682803 Clinical Trial.

4

Reproducibility over time of the urinary diclofenac/4'-OH diclofenac ratio among different CYP2C9 genotypes.

Dorado P, Berecz R, Cáceres MC, Conzález I, Llerena A. Dorado P, et al. Among authors: llerena a. Eur J Drug Metab Pharmacokinet. 2003 Jul-Sep;28(3):213-5. doi: 10.1007/BF03190487. Eur J Drug Metab Pharmacokinet. 2003. PMID: 14527094

5

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM. LLerena A, et al. Eur J Clin Pharmacol. 2004 Feb;59(12):869-73. doi: 10.1007/s00228-003-0707-y. Epub 2004 Jan 16. Eur J Clin Pharmacol. 2004. PMID: 14726986 Clinical Trial.

6

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.

LLerena A, de la Rubia A, Berecz R, Dorado P. LLerena A, et al. Pharmacopsychiatry. 2004 Mar;37(2):69-73. doi: 10.1055/s-2004-815528. Pharmacopsychiatry. 2004. PMID: 15048614

7

QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.

Llerena A, Berecz R, Dorado P, de la Rubia A. Llerena A, et al. J Psychopharmacol. 2004 Jun;18(2):189-93. doi: 10.1177/0269881104042618. J Psychopharmacol. 2004. PMID: 15260906

8

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.

Dorado P, Berecz R, Cáceres MC, González I, Cobaleda J, Llerena A. Dorado P, et al. Among authors: llerena a. Clin Chem Lab Med. 2005;43(3):275-9. doi: 10.1515/CCLM.2005.046. Clin Chem Lab Med. 2005. PMID: 15843230

9

Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.

Dorado P, Cáceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A. Dorado P, et al. Among authors: llerena a. Biotechniques. 2005 Oct;39(4):571-4. Biotechniques. 2005. PMID: 16235570

10

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Dorado P, et al. Among authors: llerena a. Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):9-19. doi: 10.1517/17425255.3.1.9. Expert Opin Drug Metab Toxicol. 2007. PMID: 17269891 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

254 results

Search Page

Filters